Aussies at ASCO

Australian oncologists were out in force at the ASCO Annual Meeting in Chicago earlier this month.

Strong results from KEYNOTE trials for melanoma were reported by several lead investigators, including Professor Georgina Long of Melanoma Institute Australia who spoke about KEYNOTE 029.

In the single-armed safety and tolerability study, 153 patients with metastatic melanoma received pembrolizumab 2 mg/kg in combination